NHF: Health Insurer - The Price the Government Sets for You
NHF: Health Insurer - The Price the Government Sets for You
In a Nutshell
Executive Summary
In a Nutshell
nib holdings is Australia's third-largest private health insurer, covering residents, international students, and visiting workers across Australia and New Zealand. At A$6.52 versus a fair value of A$6.49, the stock trades within 1% of fair value. The key reason to watch closely is the April 2026 government premium approval — a rate below 4.5% would compress sector margins immediately, while approval above 5.5% would accelerate the earnings recovery already underway.
Investor Profiles
| Profile | Rating | Rationale |
|---|---|---|
| Income | ★★★★☆ | The current dividend yield is 4.5%, rising to 4.8% on FY26 forecasts, with every dividend fully franked — lifting the grossed-up yield to approximately 6.9% for eligible investors. The 70% payout ratio is well-supported by APRA excess capital of $250 million, and dividends are expected to grow at 7–8% annually through FY28. This is a genuinely good fit for income investors who value franking credits. |
| Value | ★★★☆☆ | At 14.7x forward earnings, nib trades at a 25% discount to peer Medibank's ~19x multiple — a gap driven by New Zealand losses and the Travel division overhang, both of which are visibly resolving. Fair value of A$6.49 sits within 1% of the current price, so there is limited margin of safety at today's levels. The re-rating catalyst exists, but it requires patience rather than a near-term price correction to buy into. |
| Growth | ★★☆☆☆ | Revenue is growing at 7–8% annually, supported by government-approved premium increases of roughly 5.5–6% plus above-system policyholder growth of 3.2%. Earnings per share growth moderates from 10% in FY26 to 4% by FY28 as margins compress deliberately from 7.3% toward management's 6–7% target range. This is a steady compounder, not a high-growth opportunity — not ideal for investors seeking double-digit earnings acceleration. |
| Quality | ★★★★☆ | Return on invested capital sits at 15.1% — materially above the 9% cost of capital — and the management expense ratio has reached a nine-year low of 16.5%, underpinned by AI-driven claims automation saving $39 million cumulatively since FY24. The business model is capital-light and cash-generative, with government-administered annual repricing providing an automatic earnings recovery floor. A narrow but durable moat makes this a genuinely good fit for quality-focused investors. |
| Thematic | ★★☆☆☆ | Healthcare cost inflation is structural, ageing demographics support long-term private health insurance participation, and the Pacific Australia Labour Mobility scheme creates a growing captive market for nib's international health insurance. However, nib is a regulated insurer rather than a pure-play disruptor — thematic exposure exists but is muted by the oligopoly structure and government pricing framework. Not ideal for investors seeking concentrated thematic exposure to healthcare technology or digital health. |
nib suits income investors best. The fully franked 4.8% forward yield, supported by strong excess capital, a conservative 70% payout ratio, and government-backstopped earnings growth, delivers reliable after-tax income with a structural inflation-protection mechanism built into the revenue line. For investors in the 40s–60s demographic seeking defensive, franking-eligible income from a financially sound business, nib is a natural fit.
Executive Summary
nib holdings sells private health insurance to Australian residents, New Zealand residents, international students, and Pacific migrant workers. It earns the spread between government-approved premiums and claims paid, with profitability determined by how closely claims inflation tracks premium approvals each year.
In FY25, nib grew group revenue 7.8% to $3.6 billion and delivered underlying operating profit of $239 million — a modest decline from $258 million the prior year, driven by New Zealand claims losses and softer investment income. Australia's core residential business held steady with a 7.3% margin. New Zealand returned to profitability in the first half of FY26, removing the largest single drag on group earnings.
The investment case rests on three converging factors: above-system policyholder growth (3.2% versus an industry average of roughly 2.5%) that reflects genuine distribution investment; a structural efficiency advantage from AI-driven claims processing that peers will take two to three years to replicate; and a government-administered repricing mechanism that turns claims inflation into revenue growth within twelve months. The April 2026 premium approval rate will either confirm or challenge the FY26 earnings recovery.
At A$6.52 versus a fair value of A$6.49, the stock is trading at fair value.
Results & Outlook
What happened?
FY25 was a tale of two geographies. Australian residential health insurance delivered $208 million in operating profit at a 7.3% margin — above management's own 6–7% target. New Zealand swung to a $2.9 million loss after claims inflation outpaced premium repricing, erasing $22 million of earnings relative to FY24. The Travel division remained a distraction but is now classified as held-for-sale. Management expense savings of $20 million partially offset the New Zealand drag, with the AI-driven claims platform processing 86% of claims without human intervention.
| Metric | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|
| Revenue ($M) | 3,599 | 3,891 | 4,188 | 4,484 |
| EBITDA ($M) | 274 | 297 | 318 | 333 |
| EPS (cents) | 40.2 | 44.3 | 46.8 | 48.5 |
| DPS (cents, fully franked) | 29.0 | 31.0 | 32.8 | 33.9 |
| ROIC (%) | 15.1 | 14.8 | 14.0 | 13.5 |
| Revenue growth (%) | 7.8 | 8.1 | 7.6 | 7.1 |
What's next?
Management has guided FY26 underlying operating profit of $257–267 million — a 10% recovery from FY25, anchored by New Zealand returning to profit and Australian premiums rising 5.79% from 1 April 2025. The first-half FY26 result, delivered in February 2026, showed group operating profit of $129 million, confirming the recovery is tracking at the top of guidance.
The April 2026 Department of Health premium approval is the next significant catalyst. A rate at or above 5.5% would underpin margin stability through FY27. The Travel disposal, expected to complete within twelve months, will remove the final strategic overhang and return approximately $121 million in capital — likely via a special dividend or buyback. New Zealand's second-half FY26 result, covering the winter claims season, will determine whether the recovery is durable or still fragile.
Valuation & Risks
| Metric | Value |
|---|---|
| Fair Value | A$6.49 |
| Current Price | A$6.52 |
| Upside / (Downside) | −0.5% |
| Bull Case (20% probability) | A$7.40 |
| Bear Case (20% probability) | A$5.00 |
| Severe Case (10% probability) | A$4.04 |
| Forward P/E (FY26E) | 14.7x |
| Grossed-up dividend yield (FY26E) | ~6.9% |
What could go wrong?
The single biggest risk is claims inflation re-accelerating above 6% while the government approves premium increases below 4.5%. Every one percentage point of excess claims inflation reduces operating profit by roughly $25–30 million. Unlike most industries, nib cannot reprice mid-year — it must absorb the full gap until the next annual approval cycle, compressing margins for twelve months before the mechanism corrects. This is not hypothetical: it is exactly what happened in New Zealand in FY25, turning a $19 million profit into a $3 million loss in a single year. Healthcare wage awards — locked in through multi-year Fair Work Commission determinations — are the primary transmission mechanism. If nursing and allied health wages rise above 5% again in the FY26–27 award round, claims inflation will follow within six to nine months. The bear case value of A$5.00 reflects this scenario; the severe case of A$4.04 adds a structural reduction in the government PHI rebate, which remains an active policy discussion.